Preliminary evidence for a matrix metalloproteinase-2 (MMP-2)-dependent shedding of soluble CD40 ligand (SCD40L) from activated platelets

Platelets

Volumn 20, Issue 6, 2009, Pages 441-444

  Reinboldt, Stephan ^a   Wenzel, Folker ^b   Rauch, Bernhard H ^c   Hohlfeld, Thomas ^c   Grandoch, Maria ^a   Fischer, Jens W ^a   Weber, Artur Aron ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Transfusionsmedizin der Paracelsus Medizinische Privatuniversitt ^*  (Austria)

^c Institut fur Pharmakologie und Klinische Pharmakologie   (Germany)

Author keywords

CD40L; MMP 2; Platelets; protease; sCD40L

Indexed keywords

1,10 PHENANTHROLINE; 4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; APROTININ; CD40 LIGAND; EDETIC ACID; GELATINASE A; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEPSTATIN; PROTEINASE INHIBITOR; SOLUBLE CD40 LIGAND; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PEPTIDE FRAGMENT; THROMBIN RECEPTOR PEPTIDE (42 47); THROMBIN RECEPTOR PEPTIDE (42-47);

ARTICLE; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; BLOOD; DRUG ANTAGONISM; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTE COUNT;

BLOOD PLATELETS; CD40 LIGAND; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASE 2; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PLATELET COUNT;

EID: 77953627903     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100903096684     Document Type: Article

References (28)

1. Van Kooten C, Banchereau J. Functional role of CD40 and its ligand. Int Arch Allergy Immunol 1997;113:393-399. (Pubitemid 27296293)
2. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-135. (Pubitemid 28183361)
3. Lutgens E, Gorelik L, Daemen MJAP, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5:1313-1316. (Pubitemid 29535611)
4. Mach F, Schönbeck U, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997;94:1931-1936. (Pubitemid 27113939)
5. Mach F, Schönbeck U, Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 1998;137:S89-S95. (Pubitemid 28294213)
6. Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets 2008;19:146-154. (Pubitemid 351302382)
7. Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets 2006;17:577-585. (Pubitemid 44837728)
8. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boerstma E, Zeiher AM, Simoons ML. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-1111. (Pubitemid 36337321)
9. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Fö rster R, MÜ ller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594. (Pubitemid 28157601)
10. Hermann A, Rauch BH, Braun M, Schrö r K, Weber A-A. Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001;12:74-82. (Pubitemid 32281113)
11. Aukrust P, MÜ ller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Froland SS, Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100: 614-620. (Pubitemid 29379750)
12. Viallard JF, Solanilla A, Gauthier B, Contin C, Déchanet J, Grosset C, Moreau JF, Praloran V, Nurden P, Pellegrin JL, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002;99: 2612-2614. (Pubitemid 34525455)
13. Wenzel F, Baertl A, Zimmermann N, Hohlfeld T, Giers G, Oldenburg J, Assert R. Different behaviour of soluble CD40L concentrations can be reflected by variations of preanalytical conditions. Clin Hemorheol Microcirc 2008;39:417-422. (Pubitemid 352040027)
14. Weber A-A, Hermann A, Rauch BH, Schrö r K. Molecular identity of platelet CD40 ligand (CD40L). Thromb Haemost 2001;86:718. (Pubitemid 32743295)
15. Henn V, Steinbach S, BÜ chner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001;98:1047-1054.
16. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003;107:1123-1128. (Pubitemid 36297203)
17. Furman MI, Krueger LA, Linden MD, Bernard MR, Frelinger AL, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004;43:2319-2125.
18. Zhao L, Bath PM, May J, Lösche W, Heptinstall S. P-selectin, tissue factor and CD40 ligand expression on plateletleucocyte conjugates in the presence of a GPIIb/IIIa antagonist. Platelets 2003;14:473-480. (Pubitemid 38096118)
19. Otterdal K, Pedersen TM, Solum NO. Release of soluble CD40 ligand after platelet activation. Studies on the solubilization phase. Thromb Res 2004;114:167-177. (Pubitemid 39165568)
20. Jin Y, Nonoyama S, Morio T, Imai K, Ochs HD, Mizutani S. Characterization of soluble CD40 ligand released from activated platelets. J Med Dent Sci 2001;48:23-27. (Pubitemid 33735591)
21. Weber A-A, Schrö r K. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics. Blood 2001;98:1619-1621.
22. Stampfuss J-J, Censarek P, Fischer JW, Kaber G, Rauch BH, Freidel K, Fischer U, Schulze-Osthoff K, Grosser T, Grandoch M, et al. Complete down-modulation of P-selectin glycoprotein ligand (PSGL-1) in monocytes undergoing apoptosis. Arterioslcer Thromb Vasc Biol 2008; 28:1375-1378.
23. Santos-Martínez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res 2008;121:535-542. (Pubitemid 351174273)
24. Matthies KMG, Newman JL, Hodzic A. Wngett DG. Differential regulation of soluble and membrane CD40L proteins in T cells. Cell Immunol 2006;241:47-58. (Pubitemid 44444899)
25. Aktas B, Pozgajova M, Bergmeier W, Sunnarborg S, Offermanns S, Lee D, Wagner DD, Nieswandt B. Aspirin induces platelet receptor shedding via ADAM17 (TACE). J Biol Chem 2005;280:39716-39722. (Pubitemid 41779104)
26. Menchén L, Marín Jiménez I, Arias-Salgado EG, Fontela T, Hernández-Sampelayo P, Rodríguez MC, Butta NV. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut 2009;58:920-928.
27. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A from human platelets mediates aggregation. Nature 1997;386:616-619. (Pubitemid 27175428)
28. Sawicki G, Sanders ES, Salas E, Wozniak M, Rodrigo J, Radomski MW. Localization and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost 1998;80:836-839. (Pubitemid 28521731)